Comparing short vs long radiation with immunotherapy for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rectal adenocarcinoma confirmed by biopsy.
- The tumor must be at a stage where it has grown into or through the rectal wall or spread to nearby lymph nodes but not to distant organs.
- The tumor must be within 10 cm of the anal verge.
- Your cancer must be microsatellite stable (MSS).
- You cannot have had any prior cancer treatment for this rectal cancer.
- You must be in good overall health with adequate organ function.
- You cannot have an active autoimmune disease or be on strong immunosuppressants.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a shorter course of radiation that avoids draining lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), for people with stage II or III rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink tumors while keeping lymph nodes intact.
This trial studies a shorter course of radiation for rectal cancer, followed by chemotherapy and an immune treatment called a PD-1 inhibitor. It aims to improve treatment outcomes for people with locally advanced rectal cancer that has not spread to distant organs.
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.